Quantcast
Last updated on April 24, 2014 at 13:35 EDT

Latest Antivirals Stories

2013-04-04 08:28:37

MONTREAL, April 4, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today responded to a generic approval for Zovirax® ointment. "Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment," stated J. Michael Pearson. "While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an...

2013-04-03 16:24:16

PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic version of Valeant International's Zovirax(® )Ointment, which is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes...

2013-03-28 16:25:12

-- Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease -- RARITAN, N.J., March 28, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily with...

2013-03-28 08:27:52

- CMX001 data will also be presented in a poster session RESEARCH TRIANGLE PARK, N.C., March 28, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad spectrum antiviral compound CMX001 at the European Group for Blood and Marrow Transplantation's (EBMT) Annual Meeting being held April 7-10, 2013 in London, United Kingdom. EBMT is a...

2013-03-20 23:02:51

polyDNA recommends that the public consider Gene-Eden-VIR, a natural herpes remedy with no side effects. Rochester, NY (PRWEB) March 20, 2013 polyDNA has learned that a new paper spotlights the status of recent antiviral research. (1) In one section of the paper, the authors highlight the state of affairs on anti-herpes medications. As of March 2013, a helicase-primase inhibitor (HPI) under the generic name of AIC316 and developed by AiCuris has now proceeded to phase I/II clinical trials....

2013-03-20 08:26:18

EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin(TM )(amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65(th) American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nurelin, a once-daily extended release formulation of amantadine intended for nighttime administration, is being evaluated in a Phase 2/3...

2013-03-14 08:28:24

RESEARCH TRIANGLE PARK, N.C., March 14, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that Michael D. Rogers, Ph.D., has joined the company as Chief Development Officer. Dr. Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library. "We are extremely pleased to have...

2013-02-20 08:27:50

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Ernest Mario, Ph.D., as Chairman of its Board of Directors. "Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms. His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase 3...

2013-02-19 08:31:46

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001. CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year. "These findings demonstrate CMX001's potential to be a safe and...

HIV And Other Deadly Viruses Blocked By Natural Protein
2013-02-12 04:56:31

Jason Pierce, MSN, MBA, RN for redOrbit.com — Your Universe Online A study by a team of UCLA-led researchers, published in the journal Immunity in January 2013, may aid in the development of broad spectrum medications aimed at combating existing and newly emerging viral threats. Broad spectrum antivirals can be used to treat diseases caused by a variety of different viruses. The development of these medications is a domestic biodefense goal of the National Institute of Allergy and...